NA-831™

NA-831™is a small molecule drug that can be administered orally. NA-831 exhibits neuroprotection to protect the brain from further damages. The drug exhibits strong neurogenesis, i.e. ability to generate new neurons.

It has been discovered that in Alzheimer’s patients, the ability to regenerate new neurons in the hippocampus is impaired, causing memory loss and cognitive impairment. NA-831 facilitates neurogenesis restoring memory loss and improve cognitive functions.

NA-831 which is based on mechanism of action of neurogenesis, directly related to restoring memory loss and improvement of cogntive improvement.

NA-831 can easily cross the blood brain barrier with great bioavailability, so only a small dose of the drug is required to be effective. The drug shows the following properties:

UPCOMING PHASE 3 CLINICAL TRIALS OF NA-831

Biomed plans to conduct two Phase 3 programs for NA-831:

(1) The COGNITION Program for the treatment of 375 patients with mild and moderate Alzheimer’s disease over 12 months. Age group: 65- 80 years of age.

(2) The PREVENTION Program for the prevention of 550 subjects, asymptomatic from a high risk population over 24 months. Age group: 45-70 years of age.

These trials follow strict scientific standards and regulatory requirements to protect patients and help produce reliable results.

Study physicians will review risks and potential benefits with patients and their caregivers before patients are enrolled in the clinical trials.

The Phase 3 clinical trials of NA-831 have been designed to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.